Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Alopecia 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 64Androgen Antagonists 59Abiraterone Acetate 58apalutamide 56Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Immunoconjugates × 1 year × Clear all
NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Active not recruiting
44 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡